Table 4. Estimated prevalence of... | American Society of Hematology

Table 4.

Estimated prevalence of thrombophilia in patients with VTE and risk of recurrent VTE associated with the presence of thrombophilia

Type of thrombophilia	Prevalence, median % (min-max)	RR for VTE recurrence, positive vs negative (95% CI)
Any thrombophilia	38.0 (21.6-59.5)	1.65 (1.28-2.47)
Factor V Leiden mutation, homozygous	1.5 (0.3-3.1)	2.10 (1.09-4.06)
Factor V Leiden mutation, heterozygous	17.5 (4.1-34.8)	1.36 (1.19-1.57)
Prothrombin G20210A gene mutation^a	6.1 (1.4-16.3)	1.34 (1.05-1.71)
AT deficiency	2.2 (0.2-8.7)	2.07 (1.50-2.87)
PC deficiency	2.5 (0.7-8.6)	2.13 (1.26-3.59)
PS deficiency	2.3 (0.7-7.3)	1.30 (0.87-1.94)
AT, PC, or PS deficiency	7.0 (2.5-18.4)	1.62 (1.17-2.23)
Antiphospholipid antibodies^b	9.7 (1.9-19.4)	1.92 (0.99-3.72)

Type of thrombophilia	Prevalence, median % (min-max)	RR for VTE recurrence, positive vs negative (95% CI)
Any thrombophilia	38.0 (21.6-59.5)	1.65 (1.28-2.47)
Factor V Leiden mutation, homozygous	1.5 (0.3-3.1)	2.10 (1.09-4.06)
Factor V Leiden mutation, heterozygous	17.5 (4.1-34.8)	1.36 (1.19-1.57)
Prothrombin G20210A gene mutation^a	6.1 (1.4-16.3)	1.34 (1.05-1.71)
AT deficiency	2.2 (0.2-8.7)	2.07 (1.50-2.87)
PC deficiency	2.5 (0.7-8.6)	2.13 (1.26-3.59)
PS deficiency	2.3 (0.7-7.3)	1.30 (0.87-1.94)
AT, PC, or PS deficiency	7.0 (2.5-18.4)	1.62 (1.17-2.23)
Antiphospholipid antibodies^b	9.7 (1.9-19.4)	1.92 (0.99-3.72)

Also referred to as factor II mutation; separate estimates for heterozygous/homozygous mutations are not available.

Lupus anticoagulant, anti–ß2-glycoprotein-1 IgG and IgM antibodies, anticardiolipin IgG and IgM antibodies.

Adapted with permission from Middeldorp et al.²⁷